SHERIDAN, WYOMING – July 8, 2025 – Bio-Rad Laboratories, Inc. has announced a significant expansion of its recombinant monoclonal anti-idiotypic antibody and SpyCatcher reagent portfolios, reinforcing its support for bioanalytical assay development and antibody drug discovery across the life sciences sector.
Extended antibody coverage for leading biotherapeutics
The newly introduced anti-idiotypic antibodies target a range of high-profile biologics: pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and the bispecific antibody emicizumab (Hemlibra). These additions enhance Bio-Rad’s ability to support pharmacokinetic (PK) and anti-drug-antibody (ADA) assays that are essential for monitoring both innovator and biosimilar therapies.
By expanding its coverage across these therapeutics, Bio-Rad provides researchers and drug developers with more options for developing robust and regulatory-aligned bioanalytical workflows. The antibodies are approved for in vitro research and commercial testing services, streamlining preclinical and clinical study phases as well as post-market patient monitoring.
SpyCatcher innovation drives assay flexibility
Bio-Rad has also extended its suite of SpyCatcher reagents with the addition of the Human IgM-FcSpyCatcher. This unique reagent enables rapid switching of antibody formats at the protein level, allowing spontaneous formation of pentameric and hexameric IgMs. This advancement simplifies assay design while reducing engineering bottlenecks, particularly in fast-paced development environments.
The Human IgM-FcSpyCatcher has demonstrated performance in ELISA, western blotting, and precipitation assays. It is fully compatible with Bio-Rad’s HuCAL recombinant antibody platform, offering seamless integration into existing assay systems.
Supporting scalable, customizable bioanalysis
Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad, emphasized the strategic value of the new releases, stating:
"Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies is extensive; with 45 different specificities and more than 250 antibodies, we are providing greater flexibility for the development of highly selective and highly sensitive bioanalytical assays,” said Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad. “With the addition of the new SpyCatcher protein, we are continuing to deliver new and innovative bioanalysis tools for both our custom and catalog antibody customers, driving advances in antibody drug discovery."
This statement underscores the company’s dual focus on catalog breadth and innovation, reflecting its role as a critical enabler of modern biopharmaceutical R&D.
Enabling global biologics development and testing
With the biologics sector continuing to evolve rapidly, demand for assay tools that can adapt to novel therapeutic formats has never been higher. Bio-Rad’s broadened antibody and reagent offerings directly address this need by:
- Enabling rapid assay development for established and emerging biologics
- Supporting biosimilar comparability and regulatory compliance
- Facilitating modular assay design with adaptable reagent formats
The new products reinforce Bio-Rad’s leadership in the antibody tools market, and its ongoing commitment to supporting pharmaceutical and biotech innovation.
Learn more about Bio-Rad’s anti-idiotypic antibodies or explore its SpyCatcher reagents at bio-rad.com.